

WEBINAR CYCLE

NET4 Age-Friendly

Horizon Europe Pillar 2 Global challenges and European industrial competitiveness

HOST



Willeke van Staalduinen
willeke@afedemy.eu

SPEAKER



Lela Mirtskhuleva

24.01.2023 – 10.00-12.00 CET by Zoom



This video is based upon work from COST Action NET4Age-Friendly, supported by COST (European Cooperation in Science and Technology), a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation
www.cost.eu



Image by: ©wavebreakmedia/Shutterstock.com

Webinar on Proposal preparation and Proposal template in Horizon Europe

Meeting starts at 10:00 CET



Project: 101057279 – HNN3.0

24 January 2023

www.healthncp.net



Image by: ©wavebreakmedia/Shutterstock.com

Introduction to the RIA/IA proposal template

Sasha Hugentobler, Nicole Wyss |
Euresearch



Project: 101057279 – HNN3.0

1 December 2022
Online Training

www.healthncp.net

Some Facts



Participants

Basic Rule

Evaluation Criteria

Participants in Horizon Europe

Beneficiary > with EU Funding

Legal entities based in:

- EU Member States
 - Associated Countries
 - Low and middle income Countries
-
- Countries specified in the Work Programme
 - JRC, International European Interest Organisation (e.g. CERN), entities under Union law

Participant > **without** EU Funding

Legal entities:


- Based in third countries anywhere else in the world (e.g. Switzerland)
- International organisations (e.g. UN)

Funding possible **if**:

- the EC deems this participant **essential** for your project
- the country where the participant is established has a bilateral agreement with the EU

Almost everyone is eligible to participate - Not everyone is eligible to get EU funding

Basic Rules



Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Scope

- Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials
- Test new or improved anti-viral therapeutics
- Innovative delivery systems
- Consider critical social factors: sex, gender, age, socio-economic factors, ethnicity/migration, and disability
- Apply novel approaches (e.g. AI) for rapid and reliable identification of therapeutics. Engage regulatory bodies.

Expected Outcome

- Increased knowledge on viruses with epidemic potential
- Mechanisms of action for the development of broad-spectrum anti-viral therapeutics
- Scientific and clinical communities have access to novel approaches for the development of anti-viral therapies
- Access to experimental broad-spectrum anti-viral candidates for further clinical investigation
- Therapeutic options for clinical deployment in case of an epidemic or pandemic

Type of Action: RIA

Budget: €7-8
million /project

Deadline:
13 Apr 2023

Total funded
projects: 7

Evaluation Criteria (RIAs and IAs)

EXCELLENCE

- Clarity and pertinence of the **project's objectives**.
- Soundness of the proposed **methodology**.

IMPACT

- Credibility of the **pathways** to achieve the **expected outcomes and impacts** specified in the work programme.
- Suitability and quality of the **measures to maximize expected outcomes and impacts**, as set out in the dissemination and exploitation plan, including communication activities.

QUALITY AND EFFICIENCY OF THE IMPLEMENTATION

- Quality and effectiveness of the **work plan**, assessment of **risks**.
- **Capacity and role of each participant**, and extent to which the **consortium as a whole brings** together the necessary expertise.

Research Proposal Template



1. Excellence

1. Objectives and ambition *[e.g. 4 pages]*
2. Methodology *[e.g. 14 pages]*

2. Impact

1. Project's pathways towards impact *[e.g. 4 pages]*
2. Measures to maximise impact - Dissemination, exploitation and communication *[e.g. 5 pages]*
3. Summary

1. Quality and efficiency of the implementation

1. Work plan and resources *[e.g. 14 pages – including tables]*
2. Capacity of participants and consortium as a whole *[e.g. 3 pages]*

- **Part A** is generated by the IT system, based on the information entered by the participants through the submission system in the Funding & Tenders Portal.
 - **Part B** is the narrative part that includes three sections (**Excellence, Impact and Implementation**) that each correspond to an evaluation criterion.
-
- RIAs and IAs type of actions: 45 pages
 - First stage proposals: 10 pages


Research and Innovation Actions

- **RIA** Establish new knowledge and/or explore the feasibility of a new or improved technology.
- **Funding Rate 100%**

- **IA** Produce plans & arrangements or designs for new, altered or improved products, processes or services. When applicable to use TRL (Technology Readiness Levels), then IAs have more advanced TRLs, more R&I maturity.
- **Funding Rate** 70% and for public and non-profit organizations 100%.

Template Essential Information about Clinical Studies

Template for
essential information
to be provided for
proposals including
clinical
trials/studies/investi
gations/cohorts.



Clinical Studies – Applicability/Definition

– A ‘clinical study’ ... any clinical research involving a substantial amount of work related to the observation of, data collection from, or diagnostic or therapeutic intervention on multiple or individual patients or study subjects. It includes but is not limited to clinical studies and clinical trials in the sense of the EU Clinical Trials Directive (2001/20/EC) and the Regulation (EU 536/2014).

Essential Information for Clinical Studies



provide information for **each** clinical study foreseen in the proposal into **one** single document

address each section **briefly and concisely** despite no page limitations

when information is currently **not** available, describe **source and collection** of the relevant input


provide a short explanation in case some sections **do not** apply to a study

Deliverables:

Description of the clinical study
Preparedness status
Operational feasibility



Participation of Countries not associated to Horizon Europe (e.g. Swiss Entities)



Regular updates from SERI

↳ www.horizon-europe.ch

[Factsheet](#)

State Secretariat for Education,
Research and Innovation SERI

Role as
“**Associated
Partners**”

Funding
via **SERI**

(not from the EC)

No signature
of the EU
Grant Agreement

No
Coordination but
**Work Package
Lead possible**



Image by: ©wavebreakmedia/Shutterstock.com

Scientific and Technological Excellence

Sasha Hugentobleí & Micol Nantiat |
Euíeseaích



Project: 101057279 — HNN3.0

www.healthncp.net

3 Main Rules for Proposal Check of Excellence Section

Fit to the topic requirements

HORIZON-CL4-2022-BIODIV-01-01: Understanding the role of behaviour, gender specifics, lifestyle, religious and cultural values, and addressing the role of enabling players (civil society, policy makers, financing and business leaders, retailers) in decision making

| | |
|--------------------------------------|---|
| Specific conditions | |
| Expected EU contribution per project | The Commission estimates that an EU contribution of between EUR 3.00 and 4.00 million would allow these outcomes to be addressed appropriately. Nevertheless, this does not preclude submission and selection of a proposal requesting different amounts. |
| Indicative budget | The total indicative budget for the topic is EUR 10.00 million. |
| Type of Action | Research and Innovation Actions |

Expected Outcome: In line with the EU biodiversity strategy, a successful proposal will develop knowledge and tools to understand the role of transformative change for biodiversity policy making, finance and business leaders, address the indirect drivers of biodiversity loss, and initiate, accelerate and upscale biodiversity-relevant transformative changes in our society.

The projects should address **all** of the following outcomes:

- Before approaches tackling biodiversity loss and implementing nature-based solutions that consider how behaviour, lifestyles, religious, societal and cultural values shape the choices of producers and consumers, institutions and their policy decisions.
- The drivers behind broad societal changes and transitions are taken up in the design of relevant policies, communication and engagement campaigns and other actions.
- Leverage points in those sectors with the greatest impact on biodiversity are addressed, as the role of decisive actors (civil society, education institutions, policy makers, financing and business leaders, retailers) and their inter-societal consultation is known. This includes human rights and due diligence across economic value chains, as well as the role of employment patterns for a just transition.
- The understanding of the biodiversity inter-dependencies of the SDGs has improved; IPBES and IPCC are strengthened by the contribution of European research and innovation. Approaches, tools and knowledge influence policies at the adequate level on transformative change for biodiversity – the key elements for this change are determined by the portfolio of cooperating projects (of which these projects form part).

Topic: Proposals should engage with civil society organisations – in particular those working on gender, diversity, equity and inclusion – social partners, policy makers, financing, industry and business leaders, and retailers and value-led (such as religious and cultural) institutions when addressing the role of enabling players for transformative changes in

Follow the proposal template



Horizon Europe Programme
Standard Application Form (RIA, IA)

Application form (Part A)
Project proposal – Technical description (Part B)

Version 2.0
22 April 2021

Address evaluation criteria



Application Form – Part B structure

1. EXCELLENCE

What
What is the project about?

2. IMPACT

Why
Why should we do the project? What evidence do we collect and measure in the project to demonstrate the projects value?

3. IMPLEMENTATION

How
How to achieve the objectives?

Evaluation Criteria for Excellence (RIA/IA)

- Clarity and pertinence of the **project's objectives**, and the extent to which the proposed work
- is **ambitious**, and goes **beyond the state-of-the-art**
- Soundness of the proposed **methodology**, including the underlying concepts, models, assumptions, inter-disciplinary approaches
- appropriate consideration of the **gender dimension** in research and innovation content
- and the quality of **open science practices** including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

Score = 0 to 5

Key Aspects to check for the Excellence Section

Proposed project =
within the **scope** of a
work programme
topic



Idea = **ambitious**
and goes **beyond**
the state of the art



Excellence sub-
sections =

1. Objectives and Ambition
2. Methodology



Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Scope

- Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials
- Test new or improved anti-viral therapeutics
- Innovative delivery systems
- Consider critical social factors: sex, gender, age, socio-economic factors, ethnicity/migration, and disability
- Apply novel approaches (e.g. AI) for rapid and reliable identification of therapeutics. Engage regulatory bodies.

Expected Outcome

- Increased knowledge on viruses with epidemic potential
- Mechanisms of action for the development of broad-spectrum anti-viral therapeutics
- Scientific and clinical communities have access to novel approaches for the development of anti-viral therapies
- Access to experimental broad-spectrum anti-viral candidates for further clinical investigation
- Therapeutic options for clinical deployment in case of an epidemic or pandemic

Type of Action: RIA

Budget: €7-8
million /project

Deadline:
13 Apr 2023

Total funded
projects: 7

Sub-sections in the Excellence Section

1.1

Objectives and Ambition *e.g. 4 pages*

- Objectives (relevant, measurable, verifiable, and achievable)
- Beyond state-of-the-art
- R&I maturity (TRL levels)
- Special Attention of IA-Innovation Action

1.2

Methodology *e.g. 15 pages*


Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Scope

- Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials
- Test new or improved anti-viral therapeutics
- Innovative delivery systems
- Consider critical social factors such as sex, gender, age, socio-economic factors, ethnicity/migration, and disability
- Apply novel approaches (e.g. AI) for rapid and reliable identification of therapeutics.
- Engagement with regulatory bodies

Objectives of Proposal **VIRALSTOP**



- Testing and further develop 2 anti-viral therapeutic in the lab of partner x
- First clinical study of the therapeutic in x and y hospitals of xy partners on xy patients
- Development of one new delivery system at uni xy in the lab
- Regulatory and ethical regulations regarding 3 vulnerable patient groups by 2 partners and patient organization z and y
- Development of one new algorithm for machine learning, AI and test its efficacy of detecting new candidates for anti-viral therapeutics (**incl. new AI template requirements!!**)

Sub-sections in the Excellence Section

1.1

Objectives and Ambition *e.g. 4 pages*

Check structure – clear, logical
Detail – enough to convince reviewers

1.2

Methodology *e.g. 15 pages*

- Methodology (concepts, models, specific methods). Publications and Patents as Footnote.
- Links to other national and international R&I activities
- Interdisciplinary approach
- Integration of SSH*
- Gender dimension
- Open science practices
- Research data management (FAIR* principle)

*SSH - Social Sciences and Humanities

*FAIR - Findability, Accessibility, Interoperability, and Reusability

State of the Art: Going Beyond

Purpose: explaining how the expected outcomes of the project go beyond current innovations and scientific and/or technical quality.

- Describe how your project goes beyond the state-of-the-art, and the extent the proposed work is ambitious. Indicate any exceptional ground-breaking R&I, novel concepts and approaches, new products, services or business and organisational models. Where relevant, illustrate the advance by referring to products and services already available on the market. Refer to any patent or publication search carried out.

screen **existing project**
landscape
e.g. [cordis](#) database 

examine **existing scientific**
literature

search in **patent databases**
e.g. [European patent database](#) 

Open Science



early and open sharing of
research

*e.g. through preregistration, registered
reports, pre-prints, or crowd-sourcing*

research output management
including research data
management

measures to ensure
reproducibility of research
outputs

OA to research outputs through
deposition in trusted repositories

*e.g. publications, data, software,
models, algorithms, and workflows*

participation in **open peer-review**

**involving all relevant knowledge
actors** in the co-creation of R&I
agendas and contents

Open Access



MANDATORY: Open Access of peer-reviewed scientific publications relating to their results. Publication fees are **reimbursable** only if publishing venue is full open access.

ARTICLES

Deposition in a trusted repository
at the latest upon publication

License:

CC BY or equivalent
CC BY-NC/CC BY-ND are
allowed for long-text formats



VALIDATION

Information via the repository
about any research output / tools
/ instruments needed to validate
the conclusions of the scientific
publication

METADATA

Open Access in line with the
FAIR principles, providing
information about the licensing
terms and persistent identifiers

License:

CC 0 or equivalent

Research Data Management



Responsible management of the digital research data generated in the project, in line with the FAIR principles.

Data Management Plan

regularly updated for generated and/or collected data

submitted by month 6 of project

in proposal or latest by Grant Agreement signature in cases of Public Emergency

EC Template available!

DEPOSIT

asap and according to the DMP

as open as possible as closed as necessary

in a trusted repository (EOSC if required in the call conditions)

License:

CC BY

CC 0 or equivalent (also metadata)

DATA REUSE

provide information via the repository about any research output/tools/instruments needed to re-use or validate the data

Do No Significant Harm Principle (DNSH)

In line with the European Green Deal objectives, the research and innovation activities should not do significant harm **to any of the six environmental objectives** (EU Taxonomy Regulation)

Climate change mitigation

Climate change adaptation

Sustainable use & protection of water & marine resources

Transition to a circular economy

Pollution prevention & control

Protection and restoration of biodiversity & ecosystems

The DNSH principle needs to be taken into consideration in the **scientific methodology** and **impact** of the project.

Gender Dimension in Research & Innovation



MANDATORY: explaining how the gender dimension relates to the content of the planned research and innovation activities - **not** to gender balance in the team carrying out the project.

- Describe how the gender dimension (i.e. sex and/or gender analysis) is taken into account in the project's research and innovation content [*e.g. 1 page*]. If you do not consider such a gender dimension to be relevant in your project, please provide a justification._

SEX

biological characteristics distinguish between male, female, and intersex

GENDER

socio-cultural norms, identities and relations defining *feminine & masculine*

INTERSECTIONAL FACTORS

e.g. racial or ethnic origin, age, socioeconomic status, sexual orientation, or disability

Gender Dimension in Research & Innovation



COMMON MISTAKES

- using gender stereotypes
- sex/gender taken as BINARY categories
- not considering other categories of possible influence (intersectionality)
- assigning differences automatically to sex (taking sex for gender)
- over accentuation of sex and/or gender differences without having proof of their role in the researched topic
- overlooking proofs of minimal or no differences (sex and/or gender)

Check that the objectives are quantifiable

Check that all topic requirements are addressed

Check that the proposal goes beyond the state of the art with the partners in the consortium

Check that all new AI requirements are met

Check that partners represent eg patient groups, end users and how they are involved in the methodology section

Don't have too many objectives

Don't have objectives that are not relevant regarding the topic requirement

Don't omit reference to relevant publications, patents and collaborations

Don't be vague regarding patient numbers and categories

Feedback from Evaluations Excellence Section

Evaluation Summary Reports (ESR)

Not sufficiently detailed information on number of data sets and patients for some of the clinical sites.

Co-creation and involvement of vulnerable groups is described with limited details

Use of AI is not sufficiently addressed.

The strategy for patient engagement is not sufficiently clear.

Now Your Input!

Not sufficiently detailed information on number of data sets and patients for some of the clinical sites.

Co-creation and involvement of vulnerable groups is described with limited details

Use of AI is not sufficiently addressed.

The strategy for patient engagement is not sufficiently clear.



Image by: ©wavebreakmedia/Shutterstock.com



Project: 101057279 – HNN3.0

Impact

Sasha Hugentobleí, Micol Nantiat |
Euíeseaích

1 Decembeí 2022
Online Training

www.healthncp.net

Application Form – Part B Structure

1. EXCELLENCE

What
What is the project about?

2. IMPACT

Why
Why should we do the project? What evidence do we collect and measure in the project to demonstrate the projects value?

3. IMPLEMENTATION

How
How to achieve the objectives?

Evaluation Criteria for Impact (RIA/IA)

- Credibility of the pathways to achieve the **expected outcomes and impacts** specified in the work programme,
- and the likely **scale** and **significance** of the contributions due to the project.
- Suitability and quality of the **measures to maximize expected outcomes and impacts**, as set out in the **dissemination and exploitation plan**, including **communication activities**.

Score = 0 to 5

Section 2: Impact (3 sub-chapters)

1. Project's pathways towards impact
2. Measures to maximise impact - Dissemination, exploitation and communication
3. Summary

2.1 Project's pathways towards impact *[e.g. 4 pages]*

→ Describe the **contribution** of your project results

(1) **outcomes** specified in this topic, and

(2) the **wider impacts**, in the longer term, specified in the respective destinations in the work programme.

→ Requirements and potential barriers

→ Proposals must indicate the likely **scale and significance** of the project's contribution to outcomes and impacts

Scale refers to how widespread the outcomes and impacts are likely to be.

Significance refers to the importance, or value, of those benefits.

Check out nice trainings on this:

<https://www.ucd.ie/impacttoolkit/>

<https://umcgresearch.org/-/impact-umcg>


Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Expected Outcome

- Increased knowledge on viruses with epidemic potential
- Mechanisms of action for the development of broad-spectrum anti-viral therapeutics
- Scientific and clinical communities have access to novel approaches for the development of anti-viral therapies
- Access to experimental broad-spectrum anti-viral candidates for further clinical investigation
- Therapeutic options for clinical deployment in case of an epidemic or pandemic

Outcome of the project **VIRALSTOP**



Proposal

X numbers of scientific & medical publications by all partners

A new methodology of... Developed by partners xy

Trainings for medical staff on new therapies in x hospitals in y countries reaching z patients by partners xy

The project will have found at least 2 anti-viral candidates by partners xy

X new therapies tested in the clinical setting


Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Expected Outcome

- Increased knowledge on viruses with epidemic potential
- Mechanisms of action for the development of broad-spectrum anti-viral therapeutics
- Scientific and clinical communities have access to novel approaches for the development of anti-viral therapies
- Access to experimental broad-spectrum anti-viral candidates for further clinical investigation
- Therapeutic options for clinical deployment in case of an epidemic or pandemic

Scale & Significance of the project **VIRALSTOP**



The scale:

of increased knowledge and a new therapeutic is Europe wide and global in an epidemic (example Covid)

The significance:

Improve Health and Wellbeing
Saves lives in all countries
Reduces hospital burden in all countries
Reduces stress on medical staff
Hampers the burden on the health systems
Less effect on the economy, create economic prosperity
Contribute to welfare of communities
Support Sustainable Development Goals

2.2 Measures to maximise impact - Dissemination, exploitation and communication *[e.g. 4 pages]*

- A first version of 'plan for the dissemination and exploitation including communication activities
- **Target groups**
- If exploitation is expected primarily in non-associated **third countries**, justify by explaining how that exploitation is still in the Union's interest.
- Strategy for the management of intellectual property and exploitation

Address **target groups**. How do you engage with target groups? How do you **measure** their engagement?

Plan for the dissemination and exploitation including communication activities. A plan is a **strategy**, meaning provide a **table** with info **to whom, with which method you provide what and how much of it**


Pandemic preparedness and response: **Broad spectrum antiviral therapeutics** for infectious diseases with epidemic potential (3 – Tackling diseases and reducing disease burden)

HORIZON-HLTH-2023-DISEASE-03-04

Outcome of the project

- X numbers of scientific & medical publications by all partners
- A new methodology of.... Developed by partners xy
- Trainings for medical staff on new therapies in x hospitals in y countries reaching z patients by partners xy
- The project will have found at least 2 anti-viral candidates by partners xy
- X new therapies tested in the clinical setting

Target Groups **VIRALSTOP** show how you engage with



Scientist and clinicians in country y and x

Companies in the medical sector

Medical staff in the hospitals y, x, z

Regulators in the countries a, b, c

Clinical study patient groups of size x in hospitals a and b



Plan for the dissemination and exploitation including communication activities of VIRALSTOP

| What to be disseminated and exploited | To whom | How is the method | Barriers | By whom | How much/achievements |
|--|---------------------------------|----------------------|---------------------------------|---|----------------------------|
| Product 1: a new broad spectrum anti viral candidate | Pharma companies, medical staff | New compound | Regulations; Safety, efficacy | Partner x biochemist | Number new compounds |
| Service 1: Clinical Training | Medical staff, Scientists | Software or Platform | Resources, therefore eg. online | Partner y, software developer together with partner z, <u>clinician</u> | Number of downloads clicks |

2.2 Measures to maximise impact - Dissemination, exploitation and communication *[e.g. 4 pages]*

- A first version of 'plan for the dissemination and exploitation including communication activities
- Target groups
- If exploitation is expected primarily in non-associated third countries, justify by explaining how that exploitation is still in the Union's interest.
- Strategy for the **management of intellectual property and exploitation**

Intellectual Property Rights and IP Management



Strategically consider and negotiate IPRs and IP Mgmt with your partners at the proposal stage!

How shall **results** be made **accessible** to a broader (scientific) public?

What is the **commercialization potential** of your project's results?

Which **exploitation channels** seem appropriate, and what are the most suitable forms of **IP protection**?

Addressing IP in Your Proposal



TYPE OF IPRs

Patent

Utility Model

Design

Trademark

Copyright*

Trade Secret*

* No formalities or registration

comprehensive and feasible strategy for the management of the IP generated in the project

IP strategy **underpinning** the 'credibility' of the pathways

'freedom to operate' for background IP

balance between publication of results and IP protection

additional exploitation obligations in relation to IP

clear identification of **who** owns which IP (**Results Ownership List** mandatory at the end of the project)

Addressing IP in Your Proposal



TYPE OF IPRs

Patent

Utility Model

Design

Trademark

Copyright*

Trade Secret*

* No formalities or registration



ACCESS RIGHTS

- **Free** during the project
- **Fair conditions** after the project



BACKGROUND IP

IP and know-how of each partner
prior to the project




Communication
Dissemination
Exploitation

RESULTS

IP and know-how developed **during**
the project (Results Ownership List)

Your IP Timeline

A: access rights
B: background IP
C: communication
D: dissemination
E: exploitation
R: results



2.3 Summary

→ Canvas

Specific needs, expected results, D & E & C measures, target groups, outcomes, impacts


Provide a summary of this section by presenting a **canvas** with **KIP-** Key Impact Pathways.
The canvas breaks the impact down into its component parts.

2.3 Summary

Provide a summary of this section by presenting in the canvas below the key elements of your project impact pathway and of the measures to maximise its impact.

KEY ELEMENT OF THE IMPACT SECTION

| SPECIFIC NEEDS | EXPECTED RESULTS | D & E & C MEASURES |
|--|--|--|
| <p><i>What are the specific needs that triggered this project?</i></p> <p>Example 1 Most airports use process flow-oriented models based on static mathematical values limiting the optimal management of passenger flow and hampering the accurate use of the available resources to the actual demand of passengers.</p> <p>Example 2 Electronic components need to get smaller and lighter to match the expectations of the end-users. At the same time there is a problem of sourcing of raw materials that has an environmental impact.</p> | <p><i>What do you expect to generate by the end of the project?</i></p> <p>Example 1 Successful large-scale demonstrator: Trial with 3 airports of an advanced forecasting system for proactive airport passenger flow management.</p> <p>Algorithmic model: Novel algorithmic model for proactive airport passenger flow management.</p> <p>Example 2 Publication of a scientific discovery on transparent electronics.</p> <p>New product: More sustainable electronic circuits.</p> <p>Three PhD students trained.</p> | <p><i>What dissemination, exploitation and communication measures will you apply to the results?</i></p> <p>Example 1 Exploitation: Patenting the algorithmic model.</p> <p>Dissemination towards the scientific community and airports: Scientific publication with the results of the large-scale demonstration.</p> <p>Communication towards citizens: An event in a shopping mall to show how the outcomes of the action are relevant to our everyday lives.</p> <p>Example 2 Exploitation of the new product: Patenting the new product; Licencing to major electronic companies.</p> <p>Dissemination towards the scientific community and industry: Participating at conferences; Developing a platform of material compositions for industry; Participation at EC project portfolios to disseminate the results as part of a group and maximise the visibility vis-à-vis companies.</p> |



Provide a summary of this section by presenting in the canvas below the key elements of your project impact pathway and of the measures to maximise its impact.

Specific Needs

A therapeutic against new viruses

Expected Results

A new broad therapeutic also for vulnerable groups
A new compound

D & E & C Measures

- **Exploitation:** a new compound
- **Dissemination:** Scientific and medical publications with the methodology for the new compound and therapy
- **Communication:** A campaign to the citizens of the safety and efficacy of the new therapy

Target Groups

The patients in the x hospitals of the consortium
Infected citizens
Medical Companies

Outcomes

The patients of the x hospitals can benefit from the new therapy
A major biotech company or pharma exploits the new compound
High use of the scientific and medical discovery publications

Impacts

- **Scientific:** new mode of action of a therapeutic candidate. New compounds found. Increased efficacy.
- **Economic:** a % reduction of patients with severe conditions, reduces costs of health system, hospital, work force
- **Societal:** less death, more stable economy. Provide QALY (Quality Adjusted Life Year)

DOs

&

DON'Ts

Be as concise and precise as possible

Address impact short term (duration of project)
and long term (10 years from now)

Explain well where the impact is on EU level
must be clear how results will be made available
outside of countries where partners are located

Write an excellent CANVAS

- Don't define impact in qualitative terms only
- Don't have an insufficient exploitation strategy
- Don't omit explaining the means of delivery of end results to users
- Don't be vague regarding targeted stakeholders

Feedback from Evaluations Impact Section

Evaluation Summary Reports (ESR)

Insufficient details about objectives related to communication activities

Plan how to reach acceptance for this approach is missing

The exploitation of the produced software is not enough detailed

Not enough measurable indicators to monitor progress

Now Your Input!

Insufficient details about objectives related to communication activities

Plan how to reach acceptance for this approach is missing

The exploitation of the produced software is not enough detailed

Not enough measurable indicators to monitor progress



Sasha

Hugentobler



Micol

Nantiat



www.healthncp.net

l'hank you

Euíeseaích | www.euíeseaích.ch

Sasha Hugentobleí | Micol Nantiat

sasha.Hugentobleí@euíeseaích.ch

micol.nantiat@euíeseaích.ch

#healthNCPnet



twitter.com/HealthNCPNet



www.youtube.com/channel/HealthNCPNet



www.linkedin.com/in/health-ncp-net





Image by: ©wavebreakmedia/Shutterstock.com



Project: 101057279 – HNN3.0

Quality of the Implementation (and Dos and Dons from ESR)

Bíuno Mouíenza | APRE

1st Decembeí
Online l'í aining

www.healthncp.net

Application Foím – Paít B stíuctuie

1. EXCELLENCE

What

What is the project about?

2. IMPACT

Why

Why should we do the project? What evidence do we collect and measure in the project to demonstrate the projects value?

3. IMPLEMENTATION

How

How to achieve the objectives?

www.healthncp.net

1. Excellence

1. Objectives and ambition *[e.g. 4 pages]*
2. Methodology *[e.g. 15 pages]*

2. Impact

1. Project's pathways towards impact *[e.g. 4 pages]*
2. Measures to maximise impact - Dissemination, exploitation and comm. *[e.g. 5 pages]*
3. Summary *[table]*


3. Quality and efficiency of the implementation

- 3.1 Work plan and resources *[e.g. 14 pages – including tables]*
- 3.2 Capacity of participants and consortium as a whole *[e.g. 3 pages]*

Evaluation Cíteíia foí Excellence (RIA/IA)


- Quality and effectiveness of the **work plan**, assessment of risks, and appropriateness of the **effort** assigned to work packages, and the resources overall.
- Capacity and role of each **participant**, and extent to which the **consortium** as a whole brings together the necessary expertise.

Score = 0 to 5



"IMPLEMENTATION"

Glossary



WORK PACKAGE a **major sub-division** of the proposed project

TASK **core activities** in which a Work Package is divided

DELIVERABLE a **distinct output of the project**, meaningful in terms of the project's overall objectives and constituted by a report, a document, a technical diagram, a software etc;

MILESTONES means **control points** in the project that help to chart progress - **completion of a key deliverable**, allowing the next phase of the work to begin. They may also be needed at intermediary points so that, if problems have arisen, corrective measures can be taken. A milestone may be a **critical decision point** in the project where, for example, the consortium must decide which of several technologies to adopt for further development

CRITICAL RISK **plausible event or issue that could have a high adverse impact** on the ability of the project to achieve its objectives. **Likelihood**: estimated probability that the risk will materialise even after taking account of the mitigating measures put in place. **Severity**: The relative seriousness of the risk and the significance of its effect.

3.1 Work plan and resources *[e.g. 14 pages – including tables]*

No more “governance structure”

- ✓ brief presentation of the **overall structure** of the work plan;
- ✓ timing of the different work packages and their components (**Gantt chart** or similar);
- ✓ graphical presentation of the components showing how they **inter-relate** (**Pert chart** or similar).
- ✓ **detailed work description**, i.e list of:
 - **work packages** (table 3.1a); and their **description** (table 3.1b);
 - ❖ WP Management is recommended (technically not mandatory); here you may describe the main elements of your structure, do be developed in details in the CA. Management is not evaluated at proposal level.
 - ❖ Ethics: you can include it if needed, however – following the ethic review at GAP phase – a new WP can be added by the PO (you can negotiate to merge the two ethics WPs)
 - **deliverables** (table 3.1c);
 - **milestones** (table 3.1d);
 - **critical risks**, relating to project implementation, (table 3.1e).
- ✓ **number of person months** required (table 3.1f)
- ✓ description and justification of **subcontracting** costs for each participant (table 3.1g)
- ✓ justifications for ‘**purchase costs**’ (table 3.1h); for participants where those costs exceed 15% of the personnel costs (according to the budget table in proposal part A);

Example

3.1 Work plan and resources

3.1.1 Overall structure of the work plan

XYX main goal is to introduce a novel PDSS tool by developing its individual system components, integrating them into the final system, and performing a clinical and technological assessment. The project defines a working plan based on the integration between IT, advanced mathematics and statistics, graphics applied to IT solutions, and clinical and translational research, with the final aim to obtain a tool that can apply for certification and commercialization as medical devices. The working plan will be developed as follow:

Development of the decision support tools for patients and physicians.

1. **Data Capturing:** collection and analysis of clinical, biological, and multi-OMICS data through a retrospective and a prospective multicenter clinical study (WP3). QoL and Psychological measurements will be conducted in the prospective study phase to evaluate psychological impact of the users (WP4).
2. **Knowledge extraction, learning and reasoning:** integration of all collected data for patient-specific tumours characterization. Creation of a predictive models' library and reasoning techniques for the prediction of response to IO in NSCLC patients (WP5, WP6);
3. **XAI:** development of user-engaging visual data representations and interaction tools to support patients and physicians decisions (WP4, WP7);
4. **Construction of the Platform** to integrate the patients' data and the tools developed to provide information in an accessible way (WP8).

Impact assessment and qualification for the market.

5. **Impact assessment:** overall assessment of the scientific, clinical, and socio-economic value and impacts of the tools developed in the project (WP8 and WP9).
6. **Market analysis and definition of business plans,** preparing the CE certifications, set-up of the qualification for medical devices, preparation of exploitation plans and commercial agreements (WP10).

Evaluation and monitoring of ethical, privacy and security aspects will be continuous (WP2). A constant coordination effort (WP1) will grant the achievement of the XYX goals, communicated and disseminated through the whole length of the project to general public and relevant stakeholders (WP10).

Although it takes some time to write it, the work plan should come almost last in your proposal preparation.

This is because you should carefully design first your project objectives, concept and methodology, and even most of your impact section before diving into the details of how you implement your project.

Do not do the reverse, that is to start with the WPs and then defining your objectives and concept. This will cause you to fail at defining objectives and the concept properly.


➤ Brief presentation of the overall structure of the work plan. E.g:

➤ **PERT** (Project Evaluation and Review Technique) **Chart** →

➤ **GANTT Chart**

Links among each WP (or a combination of WP) to the relevant objective(s) and/or any main conceptual/methodological aspect(s). The links can be one-to-one, one-to-many, many-to-one, or many-to-many, as needed. This table or illustration should be accompanied by text that will clearly explain all the links.

To identify **dependencies between tasks**, assign resources for each task, identify **task start and end dates**, and work out the **overall project duration**.



Example



Table 3.1b – WP Description

- On average **1-2 page(s) per WP**
- Keep **number of WPs** reasonable (between 4 and 8)
- Synthetic description of **Objectives (2 -3 lines)**
- No more than **6-7 tasks per WP**
- **Around 2-3 deliverable per WP**
- At least **1-2 Milestone per WP**
- Consider to have a ‘**Ethics**’ WP
- “**Comm&Diss**” can be split from “**Expl.**” (if needed)

For each work package:

Work package number

Work package title

⚠ Participants involved in each WP and their efforts are shown in table 3.1f. Lead participant and starting and end date of each WP are shown in table 3.1a.)

Objectives

Description of work (where appropriate, broken down into tasks), lead partner and role of participants. Deliverables linked to each WP are listed in table 3.1c (no need to repeat the information here).

Define
Activities

To produce
project
deliverables

Identified
tasks
required

So the resource
& time can be
estimated

Table 3.1c – List of Deliverables

R: Document, report (excluding the periodic and final reports)
DEM: Demonstrator, pilot, prototype, plan designs
DEC: Websites, patents filing, press & media actions, videos, etc.
DATA: Data sets, microdata, etc.
DMP: Data Management Plan
ETHICS: Deliverables related to ethics issues.
SECURITY: Deliverables related to security issues
OTHER: Software, technical diagram, algorithms, models, etc..

PU - Public, fully open, e.g. web (Deliverables flagged as public will be automatically published in CORDIS project's page)
SEN - Sensitive, limited under the conditions of the Grant Agreement
Classified R-UE/EU-R - EU RESTRICTED under the Commission Decision No2015/444
Classified C-UE/EU-C - EU CONFIDENTIAL under the Commission Decision No2015/444
Classified S-UE/EU-S - EU SECRET under the Commission Decision No2015/444

Example

| Deliverable name | WP # | Lead partner | Type | Diss. level | Delivery date |
|---------------------------------------|------|--------------|------|-------------|-----------------|
| In-depth Ethical and Legal Study | WP2 | 1 | R | CO | M36 |
| Recommendation and Evaluation Report | WP2 | 4 | R | PU | M60 |
| Clinical Database | WP3 | 6 | OTH | CO | M12,M24,M40,M54 |
| Tissue Immune Profiling Database | WP3 | 2 | OTH | CO | M24, M40 |
| Genomics and Transcriptomics Database | WP3 | 5 | OTH | CO | M24, M40 |
| Metabolomic Profiling | WP3 | ... | OTH | CO | M24, M40 |
| Circulating Biomarker Database | WP3 | --- | OTH | CO | M24, M40 |

Sort per delivery date

They become official contractual obligations under the grant agreement.

- Deliverables must be **defined carefully** and you must **provide a sufficient number** of them in order to reassure evaluators on the seriousness of the project.
- It is generally considered good practice to have **at least 1 deliverable per task** (in most cases ***at the end of the task***) to assess the quality of its achievements and justify the funding.
- For **long tasks** (more than 18 months), an **intermediary deliverable** can be useful.

Table 3.1d - List of Milestones

| # | Milestone name | Related WPs | Delivery date | Means of verification |
|---|---|------------------------------------|---------------|---|
| 1 | Set-up of the clinical study and related ethical issues | WP1, WP2, WP4, WP8, WP10 | M3 | Management operational, clinical study, ethical, and legal inventory organization in place. QoL app. Storage database. D1.1, D2.1, D4.2, D8.1, D8.5, D10.2, D10.3. |
| 2 | Technical and functional framework implemented | WP1, WP2, WP3, WP5, WP8, WP9, WP10 | M12 | Data structure for the defined architecture. Ethical aspects addressed, data acquisition system populated. Budget model and dissemination plan. D1.2, D1.3, D2.1, D3.1, |

Example

Show how you will confirm that the milestone has been attained. Refer to indicators if appropriate.

- **WHAT?:** Milestones are control points for the project.
- **WHY?:** At any given moment in the project, you can check whether you are ahead or behind schedule against the milestones plan of the proposal. If you are behind schedule, **appropriate measures** should be taken to remedy the situation.
- **WHEN?:** They should generally be placed at the end of important work packages or tasks.
- **HOW MANY?:** Overall, it is a good practice to have at least 1-2 milestones per year.
- **HOW?:** Try and link milestones to one (or more) of the existing deliverables. In doing so, you will provide means of verification to the milestones and avoid writing yet another document. Doing that will surely **save you time and work** during the project execution.

Table 3.1e - Critical Risks

Risk management is the process of identifying in advance, evaluating the probability and severity and controlling risks by implementing mitigation measures.

| Description of risks. <i>Likelihood / Severity</i> | WPs | Proposed risk-mitigation measures |
|--|-----------|---|
| 10. Retrospective data are still dishomogeneous after the first part of the project (month 12) - High/high | WP5 -7 | The model trained in this context does not require the availability of the whole dataset to be trained. One might start with the use of different data to one at a time, processing them as a whole as soon as the process of merging is completed. |
| 11. Not enough data to get meaningful results using classical data-driven approaches - Probability: Medium/Medium | WP5 -7 | We will use techniques to reduce the complexity of the model to still be able to work even in the case of paucity of data, integrate physician expertise in the models, and/or resort to jackknife or adjustment techniques. |

Example

Contingency Plans

Generally, the risks that can occur in a project are related with:

- ✓ Scheduling
- ✓ Unclear roles and responsibilities
- ✓ Financing
- ✓ Use of resources
- ✓ Technology
- ✓ Deliverable quality
- ✓ Partner commitment
- ✓ Unclear goals
- ✓ Customer or user
- ✓ Supplier or subcontractor
- ✓ Decision making
- ✓ Communication and transfer of information
- ✓ Regulations

Table 3.1f – Person months

| | WPn | WPn+1 | WPn+2 | Total Person-Months per Participant |
|-------------------------------|-----|-------|-------|-------------------------------------|
| Participant Number/Short Name | | | | |
| Participant Number/Short Name | | | | |
| Participant Number/Short Name | | | | |
| Total Person Months | | | | |

Table 3.1g – Subcontracting

Generally *core tasks* of the project should not be sub-contracted

| Participant Number/Short Name | | |
|-------------------------------|----------|--|
| | Cost (€) | Description of tasks and justification |
| Subcontracting | | |

Table 3.1h – Purchase costs

If the purchase costs (other direct costs) *exceeds 15% of the personnel costs* for that participant (according to the budget table in proposal part A).

| Participant Number/Short Name | | |
|--|----------|---------------|
| | Cost (€) | Justification |
| Travel and subsistence | | |
| Equipment | | |
| Other goods, works and services | | |
| Remaining purchase costs (<15% of pers. Costs) | | |
| Total | | |

Table 3.1h – Other cost categories

| Participant Number/Short Name | | |
|--|----------|---------------|
| | Cost (€) | Justification |
| Internally invoiced goods and services | | |

3.2 Capacity of participants and consortium as a whole [*e.g. 3 pages*]

The individual members of the consortium are described in a separate section under Part A. There is no need to repeat that information here.


- Describe the consortium. How does it match the project's objectives, and **bring together the necessary disciplinary and inter-disciplinary knowledge**. Show how this includes expertise in social sciences and humanities, open science practices, and gender aspects of R&I, as appropriate.
- Show how the partners will have **access to critical infrastructure** needed to carry out the project activities.
- Describe how the **members complement one another** (and cover the value chain, where appropriate)
- In what way does each of them contribute to the project? Show that each has a **valid role, and adequate resources** in the project to fulfil that role.
- If applicable, describe the **industrial/commercial involvement** in the project to ensure exploitation of the results and explain why this is consistent with and will help to achieve the specific measures which are proposed for exploitation of the results of the project (see section 2.2).
- **Other countries and international organisations:** If one or more of the participants requesting EU funding is based in a country or is an international organisation that is not automatically eligible for such funding (entities from Member States of the EU, from Associated Countries and from one of the countries in the exhaustive list included in the Work Programme General Annexes B are automatically eligible for EU funding), explain why the participation of the entity in question is essential to successfully carry out the project.

Consortium as a whole

A combination of complementary expertise and resources available in Europe-wide different research institutes and SMEs has been established in the consortium ensuring the critical mass required to accomplish the foreseen work packages and tasks of the proposed project. Additionally, each one of the participating groups is expected, through the exchange of technical knowledge and co-operation, to promote its expertise at a higher rate leading to an accelerated progress at a European level.

A total number of thirty partners have been selected to cover the work programme of the VIP Products allocated in eleven work packages. Eleven partners are **SMEs** and have been scheduled to share the 30% of the total EU requested contribution. One large company participates in the VIP Products consortium.

An active engagement of *International Cooperation Partner Countries* has been established in VIP Products consortium. Apart from the European participants four partners from ICPC participate: IBFC from China, ARC from South Africa, and ITTLA from Mexico and INDEAR from Argentina.



Example

- Illustrate how the consortium can achieve the specific objectives of the project. Of course, not all the partners participate in all the objectives.
- Provide in just a few lines some arguments to justify the expertise such as by listing past similar achievements or participations in relevant projects.
- Infrastructure and equipment relevant to the project that each partner brings to the consortium.
- Industrial or commercial partners: demonstrate their capacity to exploit the results of the project.

Description of partner's competences and involvement/role(s)

| Competences | Role |
|---|---|
| <p>1- Ben 1 Italian no-profit research organization. Competences in <i>XXXX</i>: Project Management and stakeholders engagement: <i>XXXX</i> has an extensive and long-lasting leadership experience in medium and large size projects (35 in the Framework Programmes). Stakeholders' engagement and co-creation activities in energy related EU funded projects (XPRESS, W4RES, Super-I, MARINA and RURITAGE). Communication and Dissemination of projects' results to different target audiences. Capacity building.</p> | <p>WP6 Leader (Project Management) Task 1.2, Task 1.3, Task 2.1 and Task 5.3 Leader</p> |
| <p>2 - Ben 2 <i>XXXX</i> is a research-intensive university, a member of the UK Russell Group of leading research universities. Within the Economics Department, the Macro-Finance research cluster's research also carries important links with finance, where several ESRC-funded projects are under way, employing theoretical and empirical analysis to interrogate the relationships between financial markets and the macro economy, and their influence on WP3 Leader (Financial analysis) and Scientific Coordinator risk premia and asset pricing. Currently, <i>XXXX</i> Scientific Coordinator and WP leader for the project XPRESS (EU project 857831) and of the recently funded project SUPER-i (EU project 101028220): <i>XXXX</i> would build up on the financial and economic analysis carried out during these two projects.</p> | <p>WP3 Leader (Financing, techno-economic analysis and survey) Task 3.1, Task 3.3 and Task 3.4 leader</p> |
| <p>3 - Ben XX <i>XXXX</i> builds on the £400m invested by the Energy Technologies Institute in low-carbon energy, and the key works and intellectual property obtained in the execution of projects such as Perawat and Redapt which were formative in the acceleration of marine energy products and services. The <i>XXXX</i> will be able to offer technical and commercial skills and experience in marine energy, and a solid background in the innovation of complex systems</p> | <p>Task 1.4 and Task 3.2 leader</p> |

Example 1

Example II

Complementarity of the partnership per competence:

| n. | Short name | Main Tasks involved | Major competences used in the project |
|----|------------|---------------------------------|---|
| 1 | Partner 1 | WP1 and T6.4 leader | Experience in Project Management as project coordinator (6 in HORIZON 2020, 17 in FP7, 4 in FP6) A national hub of research and innovation related information and multiplier throughout different stakeholders. is the host organization of the Italian National Contact Points for all the themes and sectors of HORIZON 2020. has a consolidated long lasting experience in dissemination activities towards policy makers (national and regional) and stakeholders (researchers, industry, SMEs, NGOs and civil society in general). |
| 2 | Partner 2 | WP4 and T2.3, T4.3, T4.4 leader | an Italian SME with nearly 25 years of experience in the advertising, communication and promotion domain will lead WP1 and contribute actively to 1 in tasks of the project. supported some important citizen engagement and communication initiatives for customers like Coca-cola, Honeywell, P&G, Philips and other, directly or in cooperation with some of the most relevant PR and communication agencies like Cohn and Wolfe, Ketchum, Young & Rubicam, McCann-Erickson, Saatchi & Saatchi. is specialized in design and implement ICT and new media solutions for advertising and communication, with a market oriented focus. has also a long expertise in design and implementation of social media communities was leader of Impact and Dissemination workpackages in several research projects (LEILA, L4S, UPDESIGN, MEAL, HELP4MOOD). Actually is involved in 2 Coordinated and Support Actions: BIOWAYS H2020-REFLECTIVE-SOCIETY-2015 - CSA 693796 in Bio-based domain) and DANDELION, H2020-BBI-PPP-2015 - CSA 720762 in the SSH domain and, dealing with increasing impact and valorisation of research results. has 16 years of experience in EU co-funded projects. |
| 3 | Partner 3 | WP5 and T5.1 leader | Based in Slovakia, is a private Slovak consultancy specialising in entrepreneurship and business development through all its phases. Since 2009, the company managed to establish long-term relationships with European and international associations and companies, and contributed significantly to the creation and growth of several businesses. The staff of has long track-record of implementing stakeholder dialogue and citizen awareness activities not only in the framework of various EU funded projects. L will lead WP2. |
| 4 | Partner 4 | T4.1, T4.2 leader | with IRPPS has a strong multidisciplinary skills on the Social informatics, Digital ecosystems, Web applications, Knowledge sharing systems, Social Networking and participatory methodologies. In particular will provide the social pl in WP4 personalising the functionalities of the PLAKSS Framework. |
| 5 | Partner 5 | WP3 and T3.2 leader | <ul style="list-style-type: none"> Project coordination (CEED TECH); WP leadership (INSEC, DISCOVER-IT, DANDELION, BIOWAYS) Portfolio of more than 500 interdisciplinary (including bioeconomy) project/product/business development consultancy projects Implementation of more than 200 organisational, sectorial, regional, national and international strategic planning processes using public engagement. Implementation of ca 100 events for knowledge transfer, awareness raising and promotion. |
| 6 | Partner X | WP6 and T6.1, T6.2 leader | <ul style="list-style-type: none"> Marketing Communication, Integrative and creative communication to interact and inform. Manage, inform and communicate efficiently through the web. For productivity, collaboration and business Individual tailored marketing strategic guidance and advice for identifying appropriate marketing campaigns Organisation of 2 editions of the European Researchers' Night Portugal Participation at the www.securepart.eu project with implementation of an MMI approach |

Skill/competence matrix

The XX consortium has been set up with expert partners in all relevant key topics (health literacy, mapping, stakeholder engagement, co-creation, capacity building, impact assessment) and are thanks to these complementary

| | Skills | | | | | | |
|---------------|---|---|---|--|---|---|---|
| | Sample Text | Sample Text | Sample Text | Sample Text | Sample Text | Sample Text | Sample Text |
| Team Member A |  |  |  |  |  |  |  |
| Team Member B |  |  |  |  |  |  |  |
| Team Member C |  |  |  |  |  |  |  |
| Team Member D |  |  |  |  |  |  |  |
| Team Member E |  |  |  |  |  |  |  |
| Team Member F |  |  |  |  |  |  |  |
| Team Member G |  |  |  |  |  |  |  |
| Team Member H |  |  |  |  |  |  |  |

Placeholder

This is a sample text.
Insert your desired text
here.



No
Competence



Low
Competence



Some
Competence



High
Competence



Expert

Example

Feedbacks from evaluatoís (ESR)

It is missing a chart (Pert). The Gantt chart and the implementation work packages **do not clearly show an agile or versioned approach** to refine and validate developments.

Timeline of this intensive and over-ambitious programme of activities **may not be realistic**

The Gantt chart is elaborated only at work package level, the timing of tasks is not included

Some parts of the work plan are not described with enough detail to convincingly demonstrate their alignment with project objectives

The list of milestones does not allow adequate project monitoring

Some of the risks especially those related to some crucial aspects are **lacking sufficient information**

Some competences regarding disciplines are **less obvious in the consortium**

Some important deliverables for reporting on the clinical study progress are **not adequately addressed**



www.healthncp.net

I'hank you

APRE | <https://apie.it/en/homepage/>

Bíuno Mouíenza |
mouíenza@apie.it



#healthNCPnet



twitter.com/HealthNCPNet



www.youtube.com/channel/HealthNCPNet



www.linkedin.com/in/health-ncp-net